A xLONG® unit is a polypeptide chain designed and expressed with protein engineering technology. It mimics the structure of PEG and has similar properties as PEG: with high hydration radiu... ...
For metabolic diseases or cancers, monotherapy is usually not potent enough due to the complexity of the diseases. MultiBody® is a technology combining domains with different functions in... ...
According to the EPR (Enhanced permeability and retention) effect, xLONG® fused protein drugs can be accurately delivered into tumor tissues due to their significant hydration radius. Mean... ...
Doer Biologics published a research paper of a long-acting GLP-1R/GCGR dual-agonist fusion protein for the treatment of diabetes and obesity developed based on recombinant expression technology，it’s worth noting that this is the first case in the world.
In January 2019, Doer Biologics has closed tens of millions RMB in its first financing.
Invited by organization committee of IBC Asia, CEO Dr. Yanshan Huang and Vice President Dr. Shaoqing Yang attended the conference of “Biopharma Development & Production 2018” at Hilton Shanghai Hongqiao Hotel on the days of May 16th and 17th, 2018.
Zhejiang Doer Biologics Corporation
Address:Floor 23B, Building 2, No.452, Avenue 6, Hangzhou Economic and Technological Development Zone, China
© 2016-2020 Zhejiang Doer Biologics Corporation Copyright Record number:浙ICP备11008595号-1
Scan to follow us